Skip to content
etf.net

LFSC

GradeCNASDAQ Global Select

F/M Emerald Life Sciences Innovation ETF

Active Equity · Emerald · Inception 2024-10-30

$44.15−1.57 (−3.42%)

As of Sep 23, 2026, 2:20 PM EDT

History starts Oct 30, 2024.
Intraday session: down, 40 prints from 45.72 to 44.15. Range 43.97 to 45.64. Use the arrow keys to read each point.$44.50$45.00$45.5010 AM12 PM2 PM4 PM
Expense ratio
0.79%
Fund size
$125M
1Y return
+55.0%
Yield · Last 12 months
—
Volume · 30D
0M sh
NAV per share
$45.20
52W range
low $28.78high $48.78

The ETF.net LFSC Grade

C

42/ 100

Rank 22 of 35 in US Active Sector⁠

Confidence High

Six-pillar profile for LFSC. Scores out of 100: Cost 26, Risk 42, Mission 79, Tradability 56, Holdings 73, Durability 41. Strongest: Mission (79). Weakest: Cost (26). Leans toward Mission and Holdings.
F< 25
D≥ 25
C≥ 40
B≥ 55
A≥ 70

Score 42 of 100 sits in the C band. Bands: A ≥ 70, B ≥ 55, C ≥ 40, D ≥ 25, F < 25; the scale skips E.

  • Cost

    What you pay to own it — the expense ratio plus trading frictions, ranked within its category.
    DScore 26
    Category rank25/35 · mid-pack

  • Mission

    How faithfully it does the job it claims — tracking its mandate or index with minimal slippage.
    AScore 79
    Category rank4/9 · top 44%

  • Risk

    How violently it can move — volatility, drawdown depth, and downside capture versus its category.
    CScore 42
    Category rank24/35 · mid-pack

  • Tradability

    How cheaply and easily you can get in and out — liquidity, spread, and premium/discount stability.
    BScore 56
    Category rank16/35 · top 46%

  • Holdings

    What it actually owns — the quality, breadth, and concentration of the underlying portfolio.
    AScore 73
    Category rank9/35 · top 26%

  • Durability

    Whether it will still be here — the fund’s assets, age, flows, and issuer staying power.
    CScore 41
    Category rank26/35 · mid-pack

Graded as of Sep 22, 2026

Our read on LFSC

ETF.net Research

CAn actively managed swing at life sciences innovation, launched in 2024 and priced below the typical active US equity fund. Healthcare stock-picking in a single ticket, not a sector index.

Stated mandate

The fund is intended to provide exposure to the healthcare sector, primarily through the F/m Emerald Life Sciences Innovation ETF.

Why people hold it

  1. 010.54% buys active healthcare management for less than the median active US equity fund charges, so the stock-picking doesn't start in a fee hole.
  2. 02The portfolio sticks closely to the healthcare mandate in its filings. What the documents describe is what shows up in the holdings.
  3. 03One ticket for a specialist life sciences sleeve run by a manager making calls, rather than a rules-based sector index rebalancing on a calendar.

Worth knowing

  1. 01Thinly traded, with a modest asset base. Spreads can run wider than on giant sector funds, which makes limit orders and quiet mid-session windows worth the attention.
  2. 02Launched in October 2024, so the track record is short and any read on its risk behavior rests on limited history.
  3. 03This is a total-return vehicle, not an income one. It has not been paying distributions.

LFSC Holdings

As of Sep 20, 2026, 9:31 AM
Asset class
Stocks
Holdings
—
Top-10 weight
52%
Largest holding
TVTX7.4%

Geography

  • United States93.51%
  • United Kingdom6.49%
The fund’s holdings, weight-ordered — page 1 of 3.
#TickerCompanyWeight %SharesMarket valueIn ETFs
001TVTXTravere Therapeutics Inc7.38%147,483$9M109
002CORTCorcept Therapeutics Inc6.79%75,436$9M147
003LIVNLivaNova PLC6.49%105,381$8M129
004COGTCogent Biosciences Inc5.93%235,467$7M84
005SYRESpyre Therapeutics Inc5.76%79,500$7M90
006BLLNBilliontoone Inc4.62%54,115$6M35
007GHGuardant Health Inc4.26%30,504$5M171
008REPLReplimune Group Inc3.72%357,862$5M56
009MIRMMirum Pharmaceuticals Inc3.70%49,574$5M87
010CYTKCytokinetics Inc3.41%62,691$4M139
011AXSMAxsome Therapeutics Inc3.24%19,537$4M106
012MANEVeraDermics Inc3.09%37,030$4M56
013TMDXTransMedics Group Inc3.00%43,617$4M110
014SVRASavara Inc2.88%677,875$4M57
015NKTRNektar Therapeutics2.84%52,967$4M56

Showing 1–15 of 39 holdings

LFSC Performance

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

LFSC$15,497
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$11,723
Sep 22, 2025 to Sep 22, 2026. LFSC $15,497. SPY $11,723. Use the arrow keys to read each point.$8,980$12,976$16,971Sep 2025Mar 2026Sep 2026

Sep 22, 2025 – Sep 22, 2026

Returns run to the Sep 22, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for LFSC. Periods over one year show the average yearly return.
PeriodLFSC
Year to date+24.9%
1 month−4.4%
3 months+7.9%
1 year+55.0%
3 yearsFund is under 3 years old—per year
5 yearsFund is under 5 years old—per year
10 yearsFund is under 10 years old—per year

As of the close, with distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for LFSC
YearReturn barLFSC
2026 YTD+24.9%
2025+56.5%
2024−6.4%

Since listing, Oct 30, 2024

LFSC in the news

ETF.net Research hasn’t filed on LFSC yet — coverage lands here as it’s written.

LFSC Dividends

This fund pays no distributions.
—Last 12 months
Payout per share
—Last 12 months

No distributions in the last 12 months.

LFSC Risk

How much the fund’s monthly returns vary, scaled to a year.
26.6%
Annualised · 22 months to Aug 2026
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
1.24
vs 3-month T-bills · 22 months to Aug 2026
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
−29.7%
22 months · trough Apr 2025
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
0.91
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

LFSC Cost

Expense ratio0.79%
  • The middle half of US Active Sector funds
  • Median 0.65%

22 of the 33 US Active Sector funds charge less.

LFSC costs $79.00 a year on $10,000. The median US Active Sector fund costs $65.00.